In vivo evaluation of [11C]N-(2-chloro-5-thiomethylphenyl)- N′-(3-methoxy-phenyl)-N′-methylguanidine ([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor

Nuclear Medicine and Biology

Volumn 31, Issue 7, 2004, Pages 939-948

  Waterhouse, Rikki N ^a   Slifstein, Mark ^a   Dumont, Filip ^a   Zhao, Jun ^a   Chang, Raymond C ^a   Sudo, Yasuhiko ^a   Sultana, Abida ^a   Balter, Andrew ^a   Laruelle, Marc ^a  

^a Columbia Univ Coll Phys Surgs N ^*  (United States)

Author keywords

Glutamate; NMDA; PET; Phencyclidine; Radioligand

Indexed keywords

DEXTRO SERINE; DIZOCILPINE; GUANIDINE DERIVATIVE; ION CHANNEL; LIGAND; N (2 CHLORO 5 THIOMETHYLPHENYL) N' (3 METHOXYPHENYL) N' METHYLGUANIDINE C 11; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RO 256981; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; N (2 CHLORO 5 THIOMETHYLPHENYL) N' (3 METHOXYPHENYL) N' METHYLGUANIDINE; N-(2-CHLORO-5-THIOMETHYLPHENYL)-N'-(3-METHOXYPHENYL)-N'-METHYLGUANIDINE; PHENCYCLIDINE RECEPTOR; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; MALE; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; RECEPTOR BINDING; ANIMAL; ANTIBODY SPECIFICITY; BRAIN; CHEMISTRY; COMPARATIVE STUDY; EVALUATION; FEASIBILITY STUDY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PAPIO; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; FEASIBILITY STUDIES; GUANIDINES; MALE; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; PAPIO; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, PHENCYCLIDINE; TISSUE DISTRIBUTION;

EID: 4644272657     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2004.03.012     Document Type: Article

References (49)

1. Carroll R.C., Zukin R.S. NMDA-receptor trafficking and targeting implications for synaptic transmission and plasticity. Trends Neurosci. 25:(11):2002;571-577
2. Dingledine R., Myers S.J., Nicholas R.A. Molecular biology of mammalian amino acid receptors. Faseb J. 4:(9):1990;2636-2645
3. Kornhuber J., Weller M., Schoppmeyer K., Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transmission. 43:(Suppl):1994;91-104
4. Marino MJ, Conn PJ. Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):1-16
5. McEwenBS. Sex, stress and the hippocampus: allostasis, allostatic load and the aging process. Neurobiol Aging 23(5):921-39
6. McEwen B.S. Stress and hippocampal plasticity. Annu Rev Neurosci. 22:1999;105-122
7. Meldrum B.S. Glutamate as a neurotransmitter in the brain review of physiology and pathology. J Nutrit. 130:(4S Suppl):2000;1007S-1015S
8. Reynolds I.J. Modulation of NMDA receptor responsiveness by neurotransmitters, drugs and chemical modification. Life Sci. 47:(20):1990;1785-1792
9. Ziff E.B. Recent excitement in the ionotropic glutamate receptor field. Annal NY Acad Sci. 868:1999;465-473
10. Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database of Systematic Reviews (Online: Update Software), 2003(1): CD003154
11. Heresco-Levy U., Javitt D. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol. 8:(2):1998;141-152
12. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R.M., Charney D.S., Abi-Saab W., Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harvard Rev Psych. 7:(3):1999;125-143
13. Thomas R.J. Excitatory amino acids in health and disease. J Am Geriatrics Soc. 43:(11):1995;1279-1289
14. Turski L. The N-methyl-D-aspartate receptor complex. Various sites of regulation and clinical consequences. Arzneimittel-Forschung. 40:(5):1990;511-514
15. Christie J.M., Jane D.E., Monaghan D.T. Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. J. Pharmacol Exp Therapeut. 292:(3):2000;1169-1174
16. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur J Pharm. 268:(3):1994;335-345
17. Lynch D.R., Anegawa N.J., Verdoorn T., Pritchett D.B. N-methyl-D-aspartate receptors different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents. Mol Pharm. 45:(3):1994;540-545
18. Yamakura T., Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol. 59:(3):1999;279-298
19. Villmann C., Strutz N., Morth T., Hollmann M. Investigation by ion channel domain transplantation of rat glutamate receptor subunits, orphan receptors and a putative NMDA receptor subunit. Eur J Neurosci. 11:(5):1999;1765-1778
20. Waterhouse R.N. Imaging the PCP Site of the NMDA Ion Channel. Nucl Med Biol. 30:2003;869-878
21. Javitt D.C., Zukin S.R. Biexponential kinetics of [3H]MK-801 binding evidence for access to closed and open N-methyl-D-aspartate receptor channels. Mol Pharm. 35:(4):1989;387-393
22. Javitt D.C., Zukin S.R. Interaction of [3H]MK-801 with multiple states of the N-methyl-D-aspartate receptor complex of rat brain. Proc Nat Acad Sci US Am. 86:(2):1989;740-744
23. Hartvig P., Valtysson J., Antoni G., Westerberg G., Langstrom B., Ratti Moberg E., Oye I. Brain kinetics of (R)- and (S)-[N-methyl-11C]ketamine in the rhesus monkey studied by positron emission tomography (PET). Nucl Med Biol. 21:(7):1994;927-934
24. Kumlien E., Hartvig P., Valind S., Oye I., Tedroff J., Langstrom B. NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy. Epilepsia. 40:(1):1999;30-37
25. Shiue C.Y., Vallabhahosula S., Wolf A.P., Dewey S.L., Fowler J.S., Schlyer D.J., Arnett C.D., Zhou Y.G. Carbon-11 labelled ketamine-synthesis, distribution in mice and PET studies in baboons. Nucl Med Biol. 24:(2):1997;145-150
26. Blin J., Denis A., Yamaguchi T., Crouzel C., MacKenzie E.T., Baron J.C. PET studies of [18F]methyl-MK-801, a potential NMDA receptor complex radioligand. Neurosci Lett. 19:(1-4):1991;183-186
27. Ransom R.W., Eng W.S., Burns H.D., Gibson R.E., Solomon H.F. (+)-3-[123I]lodo-MK-801 synthesis and characterization of binding to the N-methyl-D-aspartate receptor complex. Life Sci. 46:(15):1990;1103-1110
28. Sihver S., Sihver W., Andersson Y., Murata T., Bergstrom M., Onoe H., Matsumura K., Tsukada H., Oreland L., Langstrom B., Watanabe Y. In vitro and in vivo characterization of (+)-3-[11C]cyano-dizocilpine. J Neural Transmission. 105:(2-3):1998;117-131
29. Ferrarese C., Guidotti A., Costa E., Miletich R.S., Rice K.C., de Costa B.R., Fulham M.J., Di Chiro G. In vivo study of NMDA-sensitive glutamate receptor by fluorothienylcyclohexylpiperidine [correction of fluorothienylcycloexylpiperidine], a possible ligand for positron emission tomography. Neuropharmacology. 30:(8):1991;899-905
30. Orita K., Sasaki S., Maeda M., Hashimoto A., Nishikawa T., Yugami T., Umezu K. Synthesis and evaluation of 1-(1-[5-(2′-[18F]fluoroethyl)-2- thienyl]-cyclohexyl)piperidine as a potential in vivo radioligand for the NMDA receptor-channel complex. Nucl Med Biol. 20:(7):1993;865-873
31. Reynolds I.J., Rothermund K., Rajdev S., Fauq A.H., Kozikowski A.P. [125I]thienylphencyclidine, a novel ligand for the NMDA receptor. Eur J Pharm. 226:(1):1992;53-58
32. Ametamey S.M., Samnick S., Leenders K.L., Vontobel P., Quack G., Parsons C.G., Schubiger P.A. Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor. J Receptor Signal Transduction Res. 19:(1-4):1999;129-141
33. Samnick S., Ametamey S., Leenders K.L., Vontobel P., Quack G., Parsons C.G., Neu H., Schubiger P.A. Electrophysiological study, biodistribution in mice, and preliminary PET evaluation in a rhesus monkey of 1-amino-3-[18F] fluoromethyl-5-methyl-adamantane (18F-MEM) a potential radioligand for mapping the NMDA-receptor complex. Nucl Med Biol. 25:(4):1998;323-330
34. Kokic M, Honer M, Kessler LJ, Grauert M, Schubiger PA, Ametamey SM. Synthesis and in vitro and in vivo evaluation of [11C]methyl-BIII277CL for imaging the PCP-binding site of the NMDA receptor by pet. J Recept Signal Transduct Res 2002 Feb-Nov;22(1-4):123-39
35. Dumont F., Sultana A., Waterhouse R.N. Synthesis and in vitro evaluation of N,N′-diphenyl and N-naphthyl-N′-phenylguanidines as N-methyl-D-aspartate receptor ion-channel ligands. Bioorg Med Chem Lett. 12:(12):2002;1583-1586
36. Keana J.F., McBumey R.N., Scherz M.W., Fischer J.B., Hamilton P.N., Smith S.M., Server A.C., Finkbeiner S., Stevens C.F., Jahr C., et al. Synthesis and characterization of a series of diarylguanidines that are noncompetitive N-methyl-D-aspartate receptor antagonists with neuroprotective properties. Proc Nat Acad Sci US Am. 86:(14):1989;5631-5635
37. Reddy N.L., Hu L.Y., Cotter R.E., Fischer J.B., Wong W.J., McBurney R.N., Weber E., Holmes D.L., Wong S.T., Prasad R., et al. Synthesis and structure-activity studies of N,N′-diarylguanidine derivatives. N-(1-naphthyl)-N′-(3-ethylphenyl)-N′-methylguanidine a new, selective noncompetitive NMDA receptor antagonist. J Med Chem. 37:(2):1994;260-267
38. Waterhouse R.N., Dumont F., Sultana A., Simpson N., Laruelle M. Synthesis of [11C]N-(2-chloro-5-thiomethylphenyl)-N′-(3-methoxyphenyl)-N′- methylguanidine ([11C]GMOM) a candidate PET tracer for imaging the PCP site of the NMDA ion channel. J Label Compd Radiopharm. 45:2002;955-964
39. Waterhouse R.N., Dumont F., Sultana A., Slifstein M., Sudo Y., Simpson N., Laruelle M. [11C]N-(2-chloro-5-thiomethylphenyl)-N′-(3-methoxyphenyl)- N′-methyl-guanidine ([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor synthesis and evaluation in rats and baboons. Neuroimage. 16:(3):2002;S24
40. Murray F., Kennedy J., Hutson P.H., Elliot J., Huscroft I., Mohnen K., Russell M.G.N., Grimwood S. Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. Eur J Parm. 398:2000;263-270
41. Woods R.P., Mazziotta J.C., Cherry S.R. MRI-PET registration with automated algorithm. J Comput Assist Tomogr. 17:(4):1993;536-543
42. Harada H., Kelly P.J., Cole D.J., Drummond J.C., Patel P.M. Isoflurane reduces N-methyl-D-aspartate toxicity in vivo in the rat cerebral cortex. Anesth Analg. 89:(6):1999;1442-1447
43. Hollmann M.W., Liu H.T., Hoenemann C.W., Liu W.H., Durieux M.E. Modulation of NMDA receptor function by ketamine and magnesium. Part II interactions with volatile anesthetics. Anesth Analg. 92:(5):2001;1182-1191
44. Ishizaki K., Yoon D.M., Yoshida N., Yamazaki M., Arai K., Fujita T. Intrathecal administration of N-methyl-D-aspartate receptor antagonist reduces the minimum alveolar anaesthetic concentration of isoflurane in rats. Brit J Anaesth. 75:(5):1995;636-638
45. Ishizaki K., Yoshida N., Yoon D.M., Yoon M.H., Sudoh M., Fujita T. Intrathecally administered NMDA receptor antagonists reduce the MAC of isoflurane in rats. Can J Anaesth. 43:(7):1996;724-730
46. Keita H., Henzel-Rouelle D., Dupont H., Desmonts J.M., Mantz J. Halothane and isoflurane increase spontaneous but reduce the N-methyl-D-aspartate-evoked dopamine release in rat striatal slices evidence for direct presynaptic effects. Anesthesiology. 91:(6):1999;1788-1797
47. Kuroda Y., Strebel S., Rafferty C., Bullock R. Neuroprotective doses of N-methyl-D-aspartate receptor antagonists profoundly reduce the minimum alveolar anesthetic concentration (MAC) for isoflurane in rats. Anesth Analges. 77:(4):1993;795-800
48. Martin D.C., Plagenhoef M., Abraham J., Dennison R.L., Aronstam R.S. Volatile anesthetics and glutamate activation of N-methyl-D-aspartate receptors. Biochem Pharm. 49:(6):1995;809-817
49. Nishikawa K., Maclver M.B. Excitatory synaptic transmission mediated by NMDA receptors is more sensitive to isoflurane than are non-NMDA receptor-mediated responses. Anesthesiology. 92:(1):2000;228-236